Prognostic factors for progression-free survival (PFS) in CLARINET study of lanreotide depot/autogel (LAN) vs placebo (PBO) in neuroendocrine tumors (NETs).

被引：2
|
作者：
Wolin, Edward M.
Caplin, Martyn E.
Pavel, Marianne E.
Cwikla, Jaroslaw B.
Phan, Alexandria T.
Raderer, Markus
Sedlackova, Eva
Cadiot, Guillaume
Capdevila, Jaume
Wall, Lucy
Rindi, Guido
Langley, Alison
Gomez-Panzani, Edda
Ruszniewski, Philippe B.
机构：
[1] Univ Kentucky, Lexington, KY USA
[2] Royal Free Hosp, London NW3 2QG, England
[3] Charite, D-13353 Berlin, Germany
[4] Univ Varmia & Masuria, Olsztyn, Poland
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Univ Hosp Vienna, Vienna, Austria
[7] Fac Med 1, Prague, Czech Republic
[8] Gen Teaching Hosp, Prague, Czech Republic
[9] Hop Robert Debre, Reims, France
[10] VHIO, Barcelona, Spain
[11] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland
[12] Univ Cattolica Sacro Cuore, Rome, Italy
[13] Ipsen, Les Ulis, France
[14] Hop Beaujon, Clichy La Garenne, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e15180
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15180
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Multivariate Analysis of Progression-Free Survival in the CLARINET Study of Lanreotide Autogel/Depot vs Placebo Identifies Prognostic Factors in Neuroendocrine Tumors
    Wolin, Edward M.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Phan, Alexandria T.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    PANCREAS, 2016, 45 (03) : 486 - 486
  • [2] Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study.
    Caplin, Martyn E.
    Ruszniewski, Philippe B.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Phan, Alexandria T.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wall, Lucy R.
    Rindi, Guido
    Langley, Alison
    Blumberg, Joelle
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Multivariate analysis of progression-free survival in the CLARINET study of lanreotide Autogel/Depot vs placebo identifies prognostic factors in neuroendocrine tumours
    Wolin, E.
    Caplin, M.
    Pavel, M.
    Cwikla, J.
    Phan, A.
    Raderer, M.
    Sedlackova, E.
    Cadiot, G.
    Capdevila, J.
    Wall, L.
    Rindi, G.
    Langley, A.
    Gomez-Panzani, E.
    Ruszniewski, P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S461 - S461
  • [4] Final progression-free survival (PFS) analyses for lanreotide autogel/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors (NETs): The CLARINET extension study.
    Wolin, Edward M.
    Pavel, Marianne
    Cwikla, Jaroslaw B.
    Phan, Alexandria T.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Lombard-Bohas, Catherine
    Liyanage, Nilani
    Mai, Xuan
    Thanh, Truong
    Ruszniewski, Philippe
    Caplin, Martyn E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study
    Dasari, A.
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wolin, Edward M.
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Progression-Free Survival (PFS) and Tumor Growth with Lanreotide Autogel (LAN) in Patients (Pts) with Enteropancreatic NETs: Results from CLARINET, a Randomized, Double-Blind, Placebo (Pbo)-Controlled Study
    Caplin, M.
    Ruszniewski, P.
    Pavel, M.
    Cwikla, J.
    Phan, A.
    Raderer, M.
    Sedlackova, E.
    Cadiot, G.
    Wall, L.
    Rindi, G.
    Langley, A.
    Blumberg, J.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 270 - 270
  • [7] Lanreotide Depot/Autogel (LAN) Vs. Placebo (PBO) for Carcinoid Syndrome (CS) in Patients With Neuroendocrine Tumors (NETs): Subgroup Analysis of the ELECT Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (08) : 10 - 11
  • [8] Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: The CLARINET Extension Study
    Wolin, Edward M.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Phan, Alexandria T.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Lombard-Bohas, Catherine
    Liyanage, Nilani
    Thanh, Xuan-Mai Truong
    Ruszniewski, Philippe B.
    Caplin, Martyn E.
    Investigators, Clarinet
    PANCREAS, 2018, 47 (03) : 358 - 359
  • [9] Lanreotide depot/autogel (LAN) vs. placebo (PBO) for carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs): Subgroup analysis of the ELECT study
    Vinik, Aaron
    Wolin, Edward M.
    Audry, Helene
    Gomez-Panzani, Edda
    Fisher, George A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Relative risk of adverse events with lanreotide depot/autogel (LAN) vs. placebo (PBO) in patients with intestinal and pancreatic neuroendocrine tumors (NETs).
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wolin, Edward M.
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345